Opus Genetics (IRD) Stock Price, Quote, News & History

Q: What sector and industry does Opus Genetics (IRD) operate in?

Opus Genetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Opus Genetics (IRD) Stock Price, Quote, News & History

IRDNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$2.50

-0.20-7.41%

At close: Jan 29, 4:00 PM EST

$2.50

N/A

After Hours: 7:08 PM EST

Overview

News Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$2.70

Close

$2.50

Volume / Avg.

1.08M / 581.15K

Day Range

$2.49 - $2.72

52 Wk Range

0.65 - 3.05

Market Cap

$172.41M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

1.1%

Days to Cover

2.48

Recent Opus Genetics Inc News

This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.

Vandana Singh

Viatris Eye Drops Data Shows Promise For Blurred Near Vision

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-32.86M

Investing Cash Flow (TTM)

1.21M

Financing Cash Flow (TTM)

25.83M

Free Cash Flow (TTM)

-32.86M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-5.82M

Analyst Trends and Forecast

2

Oct 25

3

Nov 25

1

Dec 25

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$142.66M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8.49

PB Ratio (TTM)

28.89

Earnings Yield % (TTM)

-74.40%

Earnings Yield % (FWD)

-15.20%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.09

Company Debt

Total Debt

$1.07M

LT Debt

$1.07M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$30.82M

Debt to Equity

0.18

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$2.70

Close

$2.50

Volume / Avg.

1.08M / 581.15K

Day Range

$2.49 - $2.72

52 Wk Range

0.65 - 3.05

Market Cap

$172.41M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

1.1%

Days to Cover

2.48

About

Sector

Health Care

Industry

Biotechnology

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline include...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Opus Genetics (IRD) stock?

A

You can purchase shares of Opus Genetics (NASDAQ:IRD) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Opus Genetics (IRD) competitors?

A

Other companies in Opus Genetics’s space includes: Kalaris Therapeutics Inc (NASDAQ:KLRS), Innate Pharma SA (NASDAQ:IPHA), Tharimmune Inc (NASDAQ:THAR), Galectin Therapeutics Inc (NASDAQ:GALT) and Humacyte Inc (NASDAQ:HUMA).

Q

What is the forecast, or price target, for Opus Genetics (IRD) stock?

A

Opus Genetics has a consensus price target of $7.44.

Q

What is the current price for Opus Genetics (IRD)?

A

The stock price for Opus Genetics (NASDAQ: IRD) is $2.5 last updated January 29, 2026 at 7:08 PM EST.

Q

Does Opus Genetics (IRD) pay a dividend?

A

There are no upcoming dividends for Opus Genetics.

Q

When is Opus Genetics (NASDAQ:IRD) reporting earnings?

A

Opus Genetics does not have any upcoming earnings scheduled.

Q

Is Opus Genetics (IRD) going to split?

A

There is no upcoming split for Opus Genetics.

Q

What sector and industry does Opus Genetics (IRD) operate in?

A

Opus Genetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Kalaris Therapeutics Inc

Galectin Therapeutics Inc

ProQR Therapeutics NV

NASDAQ:PRQR

$1.62

1.25%

Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL

$2.45

-2.39%

Eledon Pharmaceuticals Inc

NASDAQ:ELDN

$2.13

-0.93%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$2.70

Close

$2.50

Volume / Avg.

1.08M / 581.15K

Day Range

$2.49 - $2.72

52 Wk Range

0.65 - 3.05

Market Cap

$172.41M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

1.1%

Days to Cover

2.48

Recent Opus Genetics Inc News

This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.

Vandana Singh

Viatris Eye Drops Data Shows Promise For Blurred Near Vision

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-32.86M

Investing Cash Flow (TTM)

1.21M

Financing Cash Flow (TTM)

25.83M

Free Cash Flow (TTM)

-32.86M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-5.82M

Analyst Trends and Forecast

2

Oct 25

3

Nov 25

1

Dec 25

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$142.66M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8.49

PB Ratio (TTM)

28.89

Earnings Yield % (TTM)

-74.40%

Earnings Yield % (FWD)

-15.20%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.09

Company Debt

Total Debt

$1.07M

LT Debt

$1.07M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$30.82M

Debt to Equity

0.18

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$2.70

Close

$2.50

Volume / Avg.

1.08M / 581.15K

Day Range

$2.49 - $2.72

52 Wk Range

0.65 - 3.05

Market Cap

$172.41M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

1.1%

Days to Cover

2.48

About

Sector

Health Care

Industry

Biotechnology

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline include...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry